Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 278
Filter
1.
Pak J Pharm Sci ; 30(5(Special)): 1851-1855, 2017 Sep.
Article in English | MEDLINE | ID: mdl-29084657

ABSTRACT

This paper aims to compare and analyze clinical efficacy of azithromycin and pefloxacin in treatment of acute enteritis. The 160 patients with acute enteritis were randomly divided into a study group (n=80) treated with azithromycin, and a reference group (n=80) treated with pefloxacin. We compared overall treatment efficiency (markedly, effective, invalid), clinical symptoms and signs remission time (antipyretic time, antidiarrheal time, symptoms and signs disappearance time), interleukin-6 and C-reactive protein concentration before and after treatment, adverse reactions rate (nausea, abdominal pain, headache, etc.). In comparison of overall treatment efficiency of the two groups, the results showed that the study group was significantly superior to the reference group (P<0.05). In comparison of clinical symptoms and signs remission time of the two groups, the study group were significantly shorter than the reference group (P<0.05). At the same time, in comparison of levels of interleukin-6 and C-reactive protein concentration after treatment, the study group was significantly superior to the reference group (P<0.05). There was no significant difference between the two groups in incidence of adverse reactions (P<0.05). The efficacy of azithromycin for acute enteritis is better than that of pefloxacin, and it can significantly reduce clinical symptom remission time. Moreover, safe and reliable, it has great value in clinical application.


Subject(s)
Azithromycin/therapeutic use , Enteritis/drug therapy , Pefloxacin/therapeutic use , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Azithromycin/adverse effects , C-Reactive Protein/metabolism , Enteritis/blood , Enteritis/metabolism , Female , Humans , Interleukin-6/blood , Male , Middle Aged , Pefloxacin/adverse effects , Time Factors , Young Adult
2.
Article in French | MEDLINE | ID: mdl-23827273

ABSTRACT

UNLABELLED: Rhinoscleroma is a chronic granulomatous respiratory tract disease. The initial lesion site is often intra-nasal. Giant tumor presentations are rare. The authors report a case of extensive nasal rhinoscleroma. OBSERVATION: A 35-year-old African male patient consulted for a large tumor of the nose. The tumor had appeared 25 years before; the initial lesion site was intra-nasal. It presented as a small non-obstructive growth. The tumor was removed 20 years before, and recurred in an exophytic presentation. The main tumor was associated to peripheral, peri-nasal, and upper lip nodules. There was a central granuloma, bleeding on contact. Nasal obstruction was complete. The histological and bacteriological examination of a biopsy specimen confirmed the diagnosis of rhinoscleroma. Trimethoprim-sulfamethoxazole was effective on the infection. DISCUSSION: Rhinoscleroma is frequently located on the nasal mucosa, but extra-nasal giant tumor presentations are rare. It can involve the whole respiratory tract. It is endemic in developing countries. Sporadic cases have been described in non-endemic areas, among migrants. The diagnosis is proved by histology. Specific and early antibiotic therapy is effective. It avoids surgical mutilation, sequels, and recurrence.


Subject(s)
Rhinoscleroma/diagnosis , Adult , Anti-Infective Agents/therapeutic use , Disease Progression , Humans , Klebsiella Infections/complications , Klebsiella Infections/therapy , Klebsiella pneumoniae/physiology , Male , Nasal Obstruction/surgery , Nose/surgery , Pefloxacin/therapeutic use , Plastic Surgery Procedures , Rhinoscleroma/etiology , Rhinoscleroma/pathology , Rhinoscleroma/therapy , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
3.
Med Sci Monit ; 18(3): BR95-102, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22367122

ABSTRACT

BACKGROUND: The purpose of the current study is to evaluate the effects of systemic ornidazole (SO) and systemic and local compound ornidazole and pefloxacin mesylate (SCOPM/LCOMP) on the inflammatory response associated with rat experimental chronic periodontitis (ECP) in sites with subgingival debridement. MATERIAL/METHODS: Periodontitis was induced in male Sprague-Dawley rats by placing a thin steel ligature around the upper first molars and inoculating them with Porphyromonas gingivalis 381. After the successful induction of the rat ECP, the periodontitis rats were randomly divided into 3 different combined treatment groups: (A) SO with scaling and root planing (SRP); (B) SCOMP with SRP; and (C) LCOMP with SRP. After 2 weeks the effects of the treatments were evaluated based on gingivitis, plaque index, probing pocket depth, aspartate aminotransferase, alveolar bone loss, and hematoxylin-eosin staining of the region around the first molars. RESULTS: After treatment, comparison with ECP was performed. The mean percentage reductions of SBI in SO, SCOPM, and LCOPM were 27.73%, 33.61%, and 58.82%, respectively. Those of PI were 33.20%, 42.80%, and 60.00%; those of PPD were 48.66%, 55.70%, and 72.48%; those of GCF-AST were 41.64%, 49.03%, and 66.42%; and those of ABL were 41.19%, 43.63%, and 54.47%, respectively. The inflammatory score of H&E showed median scores of 2.5, 1.75, 1.63, and 0.95 for ECP, SO, SCOMP, and LCOMP, respectively. All 3 treatment groups exhibited significantly reduced inflammation indicators (P<0.05). Of the 3, group C was the most effective (P<0.05). CONCLUSIONS: Although all the combined treatment groups responded to therapy with significant resolution of the infection, adjunctive LCOMP therapy is more effective for periodontitis.


Subject(s)
Ornidazole/therapeutic use , Pefloxacin/therapeutic use , Periodontitis/drug therapy , Animals , Male , Ornidazole/administration & dosage , Pefloxacin/administration & dosage , Periodontitis/microbiology , Porphyromonas gingivalis/pathogenicity , Rats , Rats, Sprague-Dawley
4.
Clin Lymphoma Myeloma ; 8(6): 359-62, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19064402

ABSTRACT

Schnitzler's syndrome is characterized by chronic urticaria and monoclonal immunoglobulin (Ig) M gammopathy, with other features including intermittent fever, joint and/or bone pain with radiologic evidence of osteosclerosis, lymphadenopathy, enlarged liver and/or spleen, leukocytosis, and elevated erythrocyte sedimentation rate. The etiology of the syndrome remains obscure, although involvement of various cytokines has been proposed. Bone metabolism and angiogenesis markers are deregulated in Waldenström macroglobulinemia and IgM monoclonal gammopathy of unknown significance, but these markers have not been assessed in Schnitzler's syndrome. Herein, we report a patient with Schnitzler's syndrome who was treated with oral pefloxacin. Serum levels of osteoclast regulators, markers of bone remodeling and angiogenesis cytokines, were measured before treatment and serially after the initiation of treatment. High bone turnover and strikingly elevated levels of angiogenic cytokines were observed at diagnosis. Treatment with pefloxacin resulted in a normalization of the bone remodeling process and a significant reduction of angiogenic cytokines, with rapid and sustained improvement of symptoms, suggesting that these factors might be implicated in the pathophysiology of this syndrome. Furthermore, pefloxacin was proven to be an effective treatment for patients with Schnitzler's syndrome.


Subject(s)
Angiogenesis Inducing Agents/metabolism , Osteogenesis , Pefloxacin/therapeutic use , Schnitzler Syndrome/drug therapy , Anti-Infective Agents/therapeutic use , Humans , Male , Middle Aged , Schnitzler Syndrome/physiopathology
5.
Arch Dermatol ; 143(8): 1046-50, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17709664

ABSTRACT

BACKGROUND: Schnitzler syndrome is characterized by chronic urticarial rash and monoclonal IgM gammopathy and is sometimes associated with periodic fever, arthralgias, and bone pain. Current treatment is unsatisfactory. OBSERVATIONS: Eleven patients with Schnitzler syndrome were treated with oral pefloxacin mesylate (800 mg/d). In 10 patients, we observed a dramatic and sustained improvement of urticarial and systemic manifestations. Corticosteroid therapy could be stopped or reduced in 6 patients. In 9 patients, pefloxacin was administered for more than 6 months (

Subject(s)
Anti-Infective Agents/therapeutic use , Pefloxacin/therapeutic use , Schnitzler Syndrome/drug therapy , Adult , Aged , Aged, 80 and over , Anti-Infective Agents/administration & dosage , Cohort Studies , Drug Therapy, Combination , Glucocorticoids/administration & dosage , Humans , Middle Aged , Pefloxacin/administration & dosage , Retrospective Studies , Treatment Outcome
6.
Medicina (Kaunas) ; 43(4): 291-300, 2007.
Article in English | MEDLINE | ID: mdl-17485956

ABSTRACT

BACKGROUND: Acute pancreatitis is a potentially serious condition. It carries an overall mortality rate of 10-15%. Infectious complications account for approximately 80% of deaths from acute pancreatitis, and the question arises whether or not prophylactic antibiotics are useful in the prevention of these complications. Therefore, we performed an evidence-based analysis to assess the effect of available prophylactic antimicrobial treatment on the development of infected necrosis and sepsis, need for surgery, and mortality. METHODS: A comprehensive PubMed search was performed evaluating the value of prophylactic administration of parenteral antibiotics in patients with acute necrotizing pancreatitis. Only articles published in English language between January 1990 and May 2006 were included. The search strategy initially generated 692 articles related to antibiotics in the treatment of acute pancreatitis. This number was reduced to 97 publications related to clinical trials on the same topic. Finally, 10 randomized clinical trials concerning prophylactic parenteral antibiotics in patients with acute necrotizing pancreatitis were identified. We have performed a meta-analysis using the random-effects model to assess the impact of prophylactic antibiotics on development of infected pancreatic necrosis and sepsis, need for surgery, and overall mortality. RESULTS: Patients with necrotizing acute pancreatitis should receive effective antibiotic prophylaxis (i.e., carbapenems intravenously) to decrease the risk of infected necrosis and sepsis and need of surgery. CONCLUSIONS: While providing new insights into key aspects of antibiotic prophylaxis, this evidence-based analysis highlights the need for further clinical trials regarding the indications for antibiotic prophylaxis.


Subject(s)
Antibiotic Prophylaxis , Carbapenems/therapeutic use , Evidence-Based Medicine , Pancreatitis, Acute Necrotizing/complications , Pancreatitis, Acute Necrotizing/drug therapy , Sepsis/prevention & control , Carbapenems/administration & dosage , Data Interpretation, Statistical , Humans , Imipenem/administration & dosage , Imipenem/therapeutic use , Incidence , Injections, Intravenous , Necrosis/prevention & control , Odds Ratio , Pancreas/pathology , Pancreatitis, Acute Necrotizing/diagnostic imaging , Pancreatitis, Acute Necrotizing/mortality , Pancreatitis, Acute Necrotizing/pathology , Pancreatitis, Acute Necrotizing/surgery , Pefloxacin/administration & dosage , Pefloxacin/therapeutic use , Prevalence , Randomized Controlled Trials as Topic , Risk , Risk Factors , Sepsis/epidemiology , Time Factors , Tomography, X-Ray Computed
7.
Cochrane Database Syst Rev ; (3): CD003597, 2006 Jul 19.
Article in English | MEDLINE | ID: mdl-16856014

ABSTRACT

BACKGROUND: Uncomplicated acute cystitis is one of the most common bacterial infections in adults. The percentage of women who have at least one episode of acute cystitis is estimated to be between 40% to 50%. Quinolones are recommended for acute cystitis in regions where the level of resistance to other antimicrobials namely co-trimoxazole is high. However the efficacy, safety and tolerance of quinolones needs investigation. OBJECTIVES: To compare the efficacy, safety and tolerance of different quinolones in women with uncomplicated acute cystitis. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, in The Cochrane Library Issue 3, 2003), MEDLINE (1966 - September 2003), EMBASE (1988 - September 2003), reference lists of articles and abstracts from conference proceedings without language restriction. Reference lists of urology, infectious diseases and nephrology textbooks, review articles and relevant studies. SELECTION CRITERIA: Randomised and quasi-randomised controlled trials comparing two or more different quinolones in women (>/= 16 years) with uncomplicated acute cystitis were selected. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) for dichotomous outcomes with 95% confidence intervals (CI). MAIN RESULTS: We identified 11 studies enrolling 7535 women. There were no significant differences in clinical or microbiological efficacy between quinolones. Photosensitivity reactions were more frequently observed for sparfloxacin when compared to ofloxacin. Any adverse event, adverse events causing withdrawal, skin adverse events, photosensitivity reactions were more common for lomefloxacin when compared to norfloxacin. Any adverse event, adverse drug reactions, CNS adverse events were more common for ofloxacin when compared to ciprofloxacin. CNS adverse events and insomnia were more often reported for rufloxacin when compared to pefloxacin. Adverse drug reactions occurred frequently for ofloxacin than levofloxacin. Insomnia was reported more frequently for enoxacin than ciprofloxacin. AUTHORS' CONCLUSIONS: We found no significant differences in clinical or microbiological efficacy between quinolones but some differences in occurrence and spectrum of quinolone safety.


Subject(s)
Anti-Infective Agents, Urinary/therapeutic use , Cystitis/drug therapy , Acute Disease , Adult , Ciprofloxacin/therapeutic use , Female , Fluoroquinolones/therapeutic use , Humans , Levofloxacin , Norfloxacin/therapeutic use , Ofloxacin/therapeutic use , Pefloxacin/therapeutic use , Quinolones/therapeutic use , Randomized Controlled Trials as Topic
9.
Pak J Pharm Sci ; 18(4): 61-4, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16380360

ABSTRACT

In 28 children, with bacteriologically and/or serologically diagnosed typhoid fever treated at CMH, Rawalpindi in 2003, first one of the three recommended drugs (viz. chloramphenicol, amoxycillin or co-trimoxazole) was given for 7 days for defervescence to occur. In those who failed to respond a second trial of therapy with one of the other two drugs was initiated, after excluding the first drug. A second failure of therapy was taken as an indication to use pefloxacin singly. Finally, 18 (64.3%) cases responded to chloramphenicol or amoxycillin or co-trimoxazole. Pefloxacin was used in 10 (35.7%) cases. The failure rate of treatment with chloramphenicol was 50%, with amoxycillin 71.4% with co-trimoxazole 75% and 0% with pefloxacin. An analysis of the 28 cases revealed that apart from fever (in 100%), splenomegaly (in 82.1%) was the most important clinical indicator to diagnosis. along with absolute eosinopenia (in 71.4%). There were no major complications, except 2 cases with typhoid hepatitis that responded to choramphenicol and co-trimoxazole, respectively. Blood culture grew Salmonella typhi in 7 cases of which 5 (72%) were multi drug resistant S. typhi.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Pefloxacin/therapeutic use , Typhoid Fever/drug therapy , Amoxicillin/adverse effects , Amoxicillin/therapeutic use , Anti-Bacterial Agents/adverse effects , Blood Cell Count , Child , Child, Preschool , Chloramphenicol/adverse effects , Chloramphenicol/therapeutic use , Female , Humans , Liver Function Tests , Male , Pefloxacin/adverse effects , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Typhoid Fever/microbiology
11.
Prescrire Int ; 13(73): 184-6, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15499700

ABSTRACT

(1) Rare but well-documented cases of joint damage, with no other identified cause, have been reported in children treated with systemic fluoroquinolones. The joint damage usually resolves gradually after drug withdrawal and are more frequent with pefloxacin. (2) The few available paediatric trials included too few patients to identify rare adverse effects on joints, or to show a causal relationship between treatment and joint damage. (3) In practice, quinolones are an option for children only when the expected benefit outweighs the risk of joint damage. In the rare cases in which fluoroquinolone therapy is justified, ciprofloxacin is the drug of first choice. Pefloxacin should be avoided.


Subject(s)
Anti-Infective Agents/therapeutic use , Fluoroquinolones/therapeutic use , Animals , Anti-Infective Agents/adverse effects , Cartilage/pathology , Child , Contraindications , Dogs , Fluoroquinolones/administration & dosage , Fluoroquinolones/adverse effects , Humans , Joint Diseases/chemically induced , Knee Joint/drug effects , Knee Joint/pathology , Pefloxacin/adverse effects , Pefloxacin/therapeutic use , Treatment Outcome
12.
Int J Clin Pharmacol Ther ; 41(6): 267-74, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12816179

ABSTRACT

The levels of metronidazole and pefloxacin in plasma and tissue penetration of both drugs were studied after prophylactic administration to 7 patients undergoing colorectal surgery. Metronidazole (1,500 mg) and pefloxacin (800 mg) were administered as an intravenous infusion 1 hour before surgery. Mean plasma levels of pefloxacin decreased from 12.92 +/- 4.10 microg/ml at the end of the infusion to 2.18 +/- 1.03 microg/ml at 36 h. These values were above the MIC90 for E. coli (0.125 microg/ml) and E. faecalis (0.5 microg/ml), microorganisms responsible for abdominal infections. Tissue pefloxacin levels were also measured with a range from 0.72 - 7.78 microg/g in subcutaneous cell tissue, from 1.94 - 17.55 microg/g in peritoneum and from 2.76 - 21.99 microg/g in colon wall. Mean plasma concentrations of metronidazole decreased from 39.89 +/- 17.08 microg/ml at the end of the infusion to 2.63 +/- 1.11 microg/ml at 36 h. During this period, concentrations were higher than 2 microg/ml, the MIC90 value for B. fragilis, the anaerobic pathogen more frequently involved in postoperative infections after rectal and colonic surgery. Tissue metronidazole levels ranged from 3.64 - 13.37 microg/g in subcutaneous cell tissue, from 3.26 - 41.66 microg/g in peritoneum and from 6.72 - 43.12 microg/g in colon wall. The AUC/MIC values (efficacy parameter for concentration-dependent killing antibiotics such as pefloxacin and metronidazole) obtained were the following: metronidazole AUC/MIC value for B. fragilis was 173; pefloxacin AUC/MIC values for E. coli and E. faecalis were 941 and 235, respectively. The values of these parameters are higher than the recommended values to ensure efficacy, which means good exposure of the antimicrobials to the microorganisms. In conclusion, the combination of pefloxacin and metronidazole as prophylactic agents to prevent infections in patients undergoing colorectal surgery produce plasma and tissue levels above the MIC values of the main pathogens responsible for this kind of infections.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Antibiotic Prophylaxis , Digestive System Surgical Procedures , Postoperative Complications/prevention & control , Sepsis/prevention & control , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bacteroides fragilis/drug effects , Colon/surgery , Drug Combinations , Enterococcus faecalis/drug effects , Escherichia coli/drug effects , Female , Humans , Infusions, Intravenous , Male , Metronidazole/pharmacokinetics , Metronidazole/therapeutic use , Microbial Sensitivity Tests , Middle Aged , Pefloxacin/pharmacokinetics , Pefloxacin/therapeutic use , Rectum/surgery , Sepsis/etiology , Tissue Distribution
13.
Pneumologie ; 56(11): 695-703, 2002 Nov.
Article in German | MEDLINE | ID: mdl-12442211

ABSTRACT

Legionellosis is a relatively rare condition but nevertheless is associated more frequently than many other pathogens with a severe course. Therefore, establishing a diagnosis of Legionellosis remains a challenge. The most significant progress in the diagnosis of Legionellosis is antigen-testing in urine by a rapid immunochromatographic test (ICT). This is an easy to handle bedside test which provides a result within 15 minutes. Sensitivity and specificity reach 80 % and 100 %, respectively. However, the exact place of this test within algorithms of clinical decision making still remains unsettled. Macrolides, doxycycline, fluoroquinolones and ketolides, and possibly also streptogramins are drugs with definitely or most probably sufficient activity against Legionella spp. and, therefore, are appropriate candidates within empirical initial antimicrobial treatment regimen of community-acquired pneumonia. Macrolides and fluoroquinolones should be the drugs of choice for the treatment of established Legionellosis. Oral macrolides should be prefered in patients with mild to moderate pneumonia; within the macrolides, azithromycin has the most favourable profile of activity. Alternatively, ciprofloxacin, levofloxacin and moxifloxacin may be selected. In severe Legionellosis as well as independently of severity in nosocomial legionellosis and immunosuppressed patients, intravenous fluoroquinolones are first choice drugs. Alternatively, azithromycin may be used. Whether a combination treatment including azithromycin or fluoroquinolones with rifampin or azithromycin with fluoroquinolone exert superior activity remains currently unknown.


Subject(s)
Legionnaires' Disease/diagnosis , Legionnaires' Disease/drug therapy , Anti-Bacterial Agents/therapeutic use , Drug Therapy, Combination/therapeutic use , Erythromycin/therapeutic use , Humans , Pefloxacin/therapeutic use , Rifampin/therapeutic use
14.
Antibiot Khimioter ; 47(4): 13-5, 2002.
Article in Russian | MEDLINE | ID: mdl-12369138

ABSTRACT

It was shown that microbial flora isolated from the bronchial secretion of 39 patients with mucoviscidosis in 1999-2001 consisted in one third (32.8%) of S. aureus strains. Evaluation of pefloxacin efficacy in the case of monoinfection and pathogens association revealed potent antistaphylococcal effect of the drug. Positive result was demonstrated in 82.3% cases by the 7th day. Among the side effects dominated arthropathy which disappeared at the period from 3 days to 3 months after drug administration was stopped.


Subject(s)
Anti-Infective Agents/therapeutic use , Cystic Fibrosis/drug therapy , Pefloxacin/therapeutic use , Adolescent , Anti-Infective Agents/adverse effects , Bronchi/metabolism , Bronchi/microbiology , Child , Child, Preschool , Cystic Fibrosis/microbiology , Cystic Fibrosis/mortality , Humans , Pefloxacin/adverse effects
15.
Biopharm Drug Dispos ; 23(7): 293-300, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12355580

ABSTRACT

The plasma levels and tissue penetration of pefloxacin were studied after prophylactic administration to patients undergoing elective biliary surgery. Pefloxacin was administered as a single dose of 800 mg given intravenously as an infusion 1 h before surgery. Over a period of two years, cultures of bile and stone were performed after cholecystectomy in order to find the main pathogens present in the geographical area of the hospital of Txagorritxu (Vitoria, Spain), as well as to test the antimicrobial susceptibility of these bacteria to pefloxacin. Thirty seven per cent of the bile and stone cultures were positive, and 75 different species were isolated. E. coli was the predominant microorganism (25%). Other frequent microorganisms were E. faecium (9.3%), S. epidermidis (6.6%) and Cl. perfringens (6.6%). Most species isolated were susceptible to pefloxacin, with MIC(90) values of 0.125 microg/ml for E. coli, 0.5 microg/ml for S. epidermidis and 1 microg/ml for Cl. perfringens. E. faecium was resistant, with a MIC(90) value of 8 microg/ml but a MIC(50) of 4 microg/ml (intermediate). After pefloxacin infusion, adequate drug plasma levels (>MIC(90)) for the most frequent pathogens were found throughout the procedure. Elimination half-life was estimated as 22.03+/-6.91 h; the area under the concentration-time curve from zero to infinite had a value of 275.07+/-130.02 mg h/l and the values for volume of distribution at steady-state and plasma clearance were 96.48+/-28.65 L and 3.60+/-1.83 l/h, respectively. Bile pefloxacin concentrations generally exceeded the minimum inhibitory concentrations for most relevant pathogens. Drug levels in gallbladder and subcutaneous tissues were also above the MIC(90) for extended periods. Patients were observed daily throughout their hospital stay. This included examination of the surgical wound and recording of body temperature. No cases of anaerobic infection were noted in the study patients. Other constants such as hospitalization stay and time of recuperation were normal for this type of surgery. According to these results, pefloxacin presents many features that make it suitable for use as a therapeutic prophylactic agent, such as its broad spectrum of antimicrobial activity and favorable pharmacokinetic properties.


Subject(s)
Antibiotic Prophylaxis , Common Bile Duct/metabolism , Common Bile Duct/surgery , Pefloxacin/pharmacokinetics , Adult , Aged , Aged, 80 and over , Antibiotic Prophylaxis/methods , Antibiotic Prophylaxis/statistics & numerical data , Area Under Curve , Cholecystectomy/statistics & numerical data , Common Bile Duct/drug effects , Female , Humans , Infusions, Intravenous , Male , Microbial Sensitivity Tests/methods , Microbial Sensitivity Tests/statistics & numerical data , Middle Aged , Pefloxacin/administration & dosage , Pefloxacin/therapeutic use , Tissue Distribution/drug effects , Tissue Distribution/physiology
16.
Antibiot Khimioter ; 47(9): 14-7, 2002.
Article in Russian | MEDLINE | ID: mdl-12619515

ABSTRACT

Results of prospective comparative investigation of monofluoroquinolones (ciprofloxacin, ofloxacin, pefloxacin) arthropathy are presented. The trial was performed at 144 children with mucoviscidosis (aged 0.5-16) and at 37 children with aplastic anemia (aged 1.75-15). Two groups differ by necessary antibacterials regimes and hence by different abilities for arthropathy development: patients with mucoviscidosis were treated with fluoroquinolones followed by repeated short courses in combination with other antibacterials; patients with aplastic anemia--were treated permanently for a long time with low doses as monotherapy for autoinfection prophylaxis. Analysis was performed on the base of catamnesis, year growth rate, postmortal morphological investigation of the right knee joint. It was shown that quinolone arthropathy development didn't depend on treatment duration, as it developed during the first three weeks of the fluoroquinolone use, but depended on the drug, patient age and nosology. Arthropathy has favourable prognosis and was fully resolved at the period from 7 days to 3 month according to the arthropathy form (arthrologic, arthritic). Quinolones arthropathy at the children has specific features, the main one is absence of cartilage damage confirmed by morphological analysis.


Subject(s)
Fluoroquinolones/therapeutic use , Adolescent , Age Factors , Anemia, Aplastic/drug therapy , Anti-Infective Agents/therapeutic use , Body Height/drug effects , Cartilage/pathology , Child , Child, Preschool , Ciprofloxacin/therapeutic use , Cystic Fibrosis/drug therapy , Drug Administration Schedule , Female , Fluoroquinolones/administration & dosage , Fluoroquinolones/adverse effects , Humans , Infant , Joint Diseases/chemically induced , Knee Joint/drug effects , Knee Joint/pathology , Male , Ofloxacin/therapeutic use , Pefloxacin/therapeutic use , Prospective Studies , Treatment Outcome
17.
West Afr J Med ; 21(4): 302-4, 2002.
Article in English | MEDLINE | ID: mdl-12665270

ABSTRACT

In this prospective study, superficial and deep swabs of all open fractures seen at the accident and emergency unit of our hospital between January and June 2000 were taken (before wound debridement was done or anitibiotics commenced). Routine microscopy, culture and sensitivities for aerobic and anaerobic organisms were carried out on these specimens. The organisms were cultured and identified using standard techniques and the antibiotic sensitivity testing was carried out using the disc diffusion method of Stokes. Within six hours of injury, single-organism isolates were commonly found whilst after 48 hours a mixed or poly-microbial organism load were isolated. In 90% of the positive isolates, the organisms isolated form the superficial and the deep swabs were the same. The antibiotic sensitivity pattern of all the isolates shows that pefloxacin, ciprofloxacin and ceftriaxone were more effective compared to cefuroxime and amoxycillin which had substantial resistance to most of the isolates. 41 fractures were followed to union and 4 (9.7%) developed osteomyelitis.


Subject(s)
Bacterial Infections/microbiology , Fractures, Open/complications , Wound Infection/microbiology , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/therapeutic use , Bacterial Infections/epidemiology , Ceftriaxone/therapeutic use , Ciprofloxacin/therapeutic use , Combined Modality Therapy , Debridement , Developing Countries , Drug Resistance, Bacterial , Emergency Service, Hospital , Emergency Treatment , Fractures, Open/therapy , Hospitals, Teaching , Humans , Microbial Sensitivity Tests , Nigeria/epidemiology , Osteomyelitis/epidemiology , Osteomyelitis/microbiology , Patient Selection , Pefloxacin/therapeutic use , Prospective Studies , Time Factors , Wound Infection/epidemiology
20.
Antibiot Khimioter ; 46(3): 16-20, 2001.
Article in Russian | MEDLINE | ID: mdl-11548276

ABSTRACT

Data on comparative investigation of the clinical and bacteriological efficacy and tolerability of monofluoroquinolones ciprofloxacin, ofloxacin and pefloxacin are given. The results confirm good clinical efficacy of all three monofluoroquinolones and high antistaphylococcal activity of pefloxacin. Efficacy of monofluoroquinolones against P. aeruginosa and S. maltophilia was moderate--only isolation of bacteria from spetrum became lower. Tolerability of monofluoroquinolones was good. Only at 5 patients the drugs use was stopped (4 in the ciprofloxacin group and 1--in the pefloxacin group). At 2 patients it was caused by arthropathy which was drug- and age-dependent. Quinolone-arthropathy was more often in the pefloxacin group and was registered only at the children elder than 10 years old with arthrological anamnesis. This arthropathy differed from experimental one by positive outcome and full recovery in the period from 7 days to 3 months. Results of morphological investigation confirmed clinical data--no invalidizing cartilage damage was revealed.


Subject(s)
Anti-Infective Agents/therapeutic use , Ciprofloxacin/therapeutic use , Cystic Fibrosis/complications , Ofloxacin/therapeutic use , Pefloxacin/therapeutic use , Respiratory Tract Infections/drug therapy , Adolescent , Anti-Infective Agents/adverse effects , Arthritis/chemically induced , Arthritis/pathology , Child , Child, Preschool , Ciprofloxacin/adverse effects , Drug Resistance, Microbial , Female , Humans , Infant , Knee Joint/drug effects , Knee Joint/pathology , Male , Ofloxacin/adverse effects , Pefloxacin/adverse effects , Respiratory Tract Infections/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL